ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

10.10
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.10 9.70 10.50 10.10 9.975 10.10 211,828 08:00:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.83 93.71M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 10.10p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £93.71 million. Scancell has a price to earnings ratio (PE ratio) of -7.83.

Scancell Share Discussion Threads

Showing 63051 to 63075 of 66650 messages
Chat Pages: Latest  2534  2533  2532  2531  2530  2529  2528  2527  2526  2525  2524  2523  Older
DateSubjectAuthorDiscuss
18/9/2023
13:06
or the existing news incorrectly valued ?
inanaco
18/9/2023
13:02
Up 38% on what. Must be expecting big news at the US Cancer presentation - but what isn't it all data /news that is already out there?
octopus100
18/9/2023
12:48
Bermuda has been quite today ... watching from a distance
inanaco
18/9/2023
12:41
standard of care ........



Immunotherapy
Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.

The following types of immunotherapy are being used in the treatment of melanoma:

Immune checkpoint inhibitor therapy: Immune checkpoint inhibitors block proteins called checkpoints that are made by some types of immune system cells, such as T cells, and some cancer cells. These checkpoints help keep immune responses from being too strong and sometimes can keep T cells from killing cancer cells. When these checkpoints are blocked, T cells can kill cancer cells better. They are used to treat some patients with advanced melanoma or tumors that cannot be removed by surgery.
There are two types of immune checkpoint inhibitor therapy:

Pd-1 and CTL4



the Scope trial is showing efficacy above standard of care

so it becomes Very commercial

and what you don't realise every other checkpoint will need to trial with Iscib1

if the triplet treatment works


that would also apply to synergy with Modi1

inanaco
18/9/2023
12:37
Tempted to add to position.
red army
18/9/2023
12:32
we are scratching the surface .........


and as yet we had not deployed a t cell enhancer mab2811

inanaco
18/9/2023
12:30
there is no direct conflict between the t cells as they are a different class

the immunobody t cells will respond to the cytokines given off by modi

inanaco
18/9/2023
12:29
in otherwords if patients slip the net ...... treat with moditope as well

if modi is proven safe and works with a checkpoint .....

it will be safe with an immunobody

inanaco
18/9/2023
12:26
It will be recalled that the ImmunoBody® platform induces a high avidity CD8+ T cell response to tumour associated
antigens. As the Moditope® platform stimulates a potent CD4+ T cell response to modified self-antigens both
platforms are complementary relying on a response by different classes of T cell for their therapeutic effect. Thus, in
principle, a combination of ImmunoBody® and Moditope® derived therapeutics may be a powerful approach to the
treatment of both early and late stage cancers.

inanaco
18/9/2023
12:18
always worth a read
inanaco
18/9/2023
12:16
From antibody studies, vimentin expressed in all of the following tumour types:
 Breast
 Prostate
 Ovarian
 Cervical
 Endometrial
 Head and neck
 Thyroid
 Glioma
 Lung
 Melanoma
 Skin
 Testis
 Urothelial
 Renal
 Stomach
 Pancreatic
 Liver

inanaco
18/9/2023
12:14
Now Number 3 on the Leaderboard Up 38.6% at 14p on volume of 3.4 million. Just reversed the completely unjustified fall from this level at the end of June. This has a lot farther to go as we await RNS news, just remember we went above 20p in April this year in anticipation of news.
888icb
18/9/2023
12:12
While we are waiting for the Modi Scib and Glymab data a reminder of what Trinity thinks the platforms could be worth.

I think they are a little low on Moditope because we have Modi-2, 3 coming down the line.


Moditope peak sales £3.5 billion, royalties 17.5%

Immunobody " " £2.5 billion, " "

Glymabs " " £5 billion " "

Avidimab " " £8.5 billion " 8%

marcusl2
18/9/2023
12:04
Crazy mcap
wewillwin20
18/9/2023
12:03
.......it is the arrival of the "informed investors", taking stock off the uninformed, who have formed the market recently.
markingtime
18/9/2023
12:01
Must be more to this. Still possible it's just a large investor building a stake but feels like something behind the scenes.
nigelpm
18/9/2023
11:59
Will dump soon
firestarter1
18/9/2023
11:50
....no need, charlatan.Stick to chopping your wood....
markingtime
18/9/2023
11:44
GUFFAW -
You will learn

the real lozan
18/9/2023
11:39
I mean you, chum.....:-)
markingtime
18/9/2023
11:38
Clearly = EGOboy ...
"Those who seek to mislead others about what they said (and when) just love to remain ambiguous by obfuscating (ie. what some of us would term "lying" :'-))"
.
Couldn't have put it better myself

the real lozan
18/9/2023
11:31
So that's a "no" then........Those who seek to mislead others about what they said (and when) just love to remain ambiguous by obfuscating (ie. what some of us would term "lying" :'-))
markingtime
18/9/2023
11:00
The Kept Mans Diary ....

accounts signed off by

Colin

() does not mean a loss

2+2=5 ..... a result with a tolerance + or - 1

inanaco
18/9/2023
10:52
An oft repeated error here =
"Just for the record,"
2 + 2 = 5
Common practice here to speak of things that are not known
EGOboy is well versed in 2 + 2 = 5...( or even 8+ )

the real lozan
18/9/2023
10:43
.....ie....12.5p
markingtime
Chat Pages: Latest  2534  2533  2532  2531  2530  2529  2528  2527  2526  2525  2524  2523  Older